Kisspeptin-10 vs PT-141 (Bremelanotide)
Side-by-side comparison of key properties, dosing, and research.
Sexual Health & LibidoAnti-Aging & Longevity
Kisspeptin-10Sexual Health & Libido
PT-141 (Bremelanotide)- Summary
- Kisspeptin-10 is the biologically active C-terminal decapeptide of kisspeptin, an endogenous regulator of the reproductive axis. It acts upstream of GnRH to potently stimulate LH and testosterone release, and plays a key role in sexual arousal and libido.
- PT-141 (Bremelanotide) is a cyclic peptide melanocortin receptor agonist that enhances sexual desire and arousal through central nervous system mechanisms. It is FDA-approved as Vyleesi for premenopausal women with hypoactive sexual desire disorder (HSDD).
- Half-Life
- ~4 minutes (rapidly degraded); longer-acting analogs like TAK-448 are in development
- 2–3 hours
- Admin Route
- SubQ, IV
- SubQ
- Research
- —
- —
- Typical Dose
- 50–500 mcg
- 0.5–1.75 mg
- Frequency
- Once daily to every other day
- As needed (not daily)
- Key Benefits
- Potently stimulates LH and testosterone
- Enhances sexual arousal and libido
- Activates HPG axis — upstream of GnRH
- May improve fertility in hypogonadotropic hypogonadism
- Increases brain activation in sexual attraction circuits
- May restore LH pulsatility in suppressed HPG axis
- Enhances sexual desire and libido in both men and women
- Improves arousal through central nervous system activation
- Effective for psychological erectile dysfunction
- Works for female sexual arousal disorder
- May improve sexual satisfaction and intensity
- Fast-acting — effects within 45–60 minutes
- FDA-approved for HSDD in premenopausal women
- Side Effects
- Injection site reactions
- Temporary nausea
- Flushing
- Elevated LH/testosterone (intended effect)
- +1 more
- Nausea (most common — 40% of users in clinical trials)
- Facial flushing and warmth
- Transient blood pressure changes (typically increase then normalize)
- Headache
- +2 more
- Stacks With
- —
- —